GLP-1 receptor agonists reduce major adverse limb events with HR 0.59 in PAD

This is a systematic review and meta-analysis of real-world data involving over 240,000 adult patients with peripheral artery disease. The review synthesized evidence on GLP-1-based therapies, including GLP-1 receptor agonists and tirzepatide, but did not report a specific comparator. The primary outcome was major adverse limb events (MALE).

The main results showed a significant reduction in MALE with a hazard ratio (HR) of 0.59 (95% CI 0.39-0.90). For major adverse cardiovascular events (MACE), the reduction was also significant with an HR of 0.67 (95% CI 0.53-0.85). Stroke was significantly reduced with an HR of 0.75 (95% CI 0.63-0.89). The review reported significant reductions for myocardial infarction and all-cause mortality, but did not provide effect sizes, absolute numbers, or p-values for these outcomes.

Key secondary outcomes included MACE, mortality, stroke, and myocardial infarction, with data as specified above. The review did not report safety findings, including adverse event rates, serious adverse events, discontinuations, or tolerability data.

These results can be compared to prior landmark studies in the therapeutic area, but the review did not specify which prior studies were included or how they directly compared. The practice relevance notes that findings support a vascular protective profile, particularly for stroke and MACE in more homogeneous populations such as patients with diabetes.

Key methodological limitations include substantial heterogeneity in MALE results and greater variability in effect magnitude for myocardial infarction and all-cause mortality. Potential biases were not detailed, but the real-world setting and heterogeneity suggest caution in interpretation.

Clinical implications are that these findings may support considering GLP-1-based therapies for vascular protection in PAD, but the evidence is observational and does not establish causation. Practice decisions should account for the lack of safety data and heterogeneity.

Unanswered questions include the specific comparators used, detailed safety profiles, optimal dosing protocols, and long-term outcomes beyond the reported follow-up, which was not reported. Future research should address these gaps to clarify clinical utility.